MedTrace Logo

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

NCT05924620 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-06-18

No results posted yet for this study

Summary

To study the efficacy and safety of finerenone in patients with primary aldosteronism

Conditions

  • Primary Aldosteronism

Interventions

DRUG

finerenone

Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).

Sponsors & Collaborators

  • Chongqing Medical University

    lead OTHER

Principal Investigators

  • Qifu Q Li, PhD · the Chongqing Primary Aldosteronism Study (CONPASS) Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2024-03-12
Completion
2024-03-12
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05924620 on ClinicalTrials.gov